ORLANDO, Fla.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced final results of a 17-week randomized, double-blind, placebo-controlled, Phase 2 study evaluating Aranesp® (darbepoetin alfa) administered every four weeks for the treatment of anemia in cancer patients not undergoing chemotherapy and/or myelosuppressive radiotherapy, a condition known as anemia of cancer. Patients receiving Aranesp were nearly three times more likely to achieve a hematopoietic response than patients receiving a placebo (69 percent vs. 24 percent, respectively). These results were presented at the American Society of Hematology (ASH) 48th annual meeting in Orlando, Fla. (Abstract # 1304)
